Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors

Protein Science

Volumn 16, Issue 12, 2007, Pages 2626-2635

  Ikuta, Mari ^a   Kornienko, Maria ^a   Byrne, Noel ^a   Reid, John C ^a   Mizuarai, Shinji ^b   Kotani, Hidehito ^b   Munshi, Sanjeev K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cancer; Crystal structure; Kinase; Kinase inhibitor; RSK1

Indexed keywords

ANTINEOPLASTIC AGENT; LIGAND; PROTEIN INHIBITOR; S6 KINASE; S6 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; CATALYSIS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DOWNSTREAM PROCESSING; DRUG DESIGN; ENZYME INACTIVATION; ENZYME REGULATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE;

ADENOSINE TRIPHOSPHATE; AMINO ACID MOTIFS; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROPHOBICITY; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PURINES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; STAUROSPORINE;

EID: 36448992598     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.073123707     Document Type: Article

References (46)

1. Atwell, S., Adams, J.M., Badger, J., Buchanan, M.D., Feil, I.K., Froning, K.J., Gao, X., Hendle, J., Keegan, K., Leon, B.C., et al. 2004. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279: 55827-55832.
2. Bailey, S. 1994. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50: 760-763. doi: 10.1107/S0907444994003112.
3. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. 2003. The specificities of protein kinase inhibitors: An update. Biochem. J. 371: 199-204.
4. Bjorbaek, C., Zhao, Y., and Moller, D.E. 1995. Divergent functional roles for p90rsk kinase domains. J. Biol. Chem. 270: 18848-18852.
5. Breitenlechner, C.B., Kairies, N.A., Honold, K., Scheiblich, S., Koll, H., Greiter, E., Koch, S., Schafer, W., Huber, R., and Engh, R.A. 2005. Crystal structures of active Src kinase domain complexes. J. Mol. Biol. 353: 222-231.
6. Brünger, A., Adams, P.D., and Clore, G.M. 1998. Crystallography & NMR System: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54: 905-921. doi: 10.1107/S0907444998003254.
7. Clark, D.E., Errington, T.M., Smith, J.A., Frierson Jr., H.F., Weber, M.J., and Lannigan, D.A. 2005. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res. 65: 3108-3116.
8. Dalby, K.N., Morrice, N., Caudwell, F.B., Avruch, J., and Cohen, P. 1998. Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J. Biol. Chem. 273: 1496-1505.
9. De Cesare, D., Jacquot, S., Hanauer, A., and Sassone-Corsi, P. 1998. Rsk-2 activity is necessary for epidermal growth factorinduced phosphorylation of CREB protein and transcription of c-fos gene. Proc. Natl. Acad. Sci. 95: 12202-12207.
10. Fischer, P.M. 2004. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem. 11: 1563-1583.
11. Fisher, T.L. and Blenis, J. 1996. Evidence for two catalytically active kinase domains in pp90rsk. Mol. Cell. Biol. 16: 1212-1219.
12. Furet, P., Caravatti, G., Lydon, N., Priestle, J.P., Sowadski, J.M., Trinks, U., and Traxler, P. 1995. Modelling study of protein kinase inhibitors: Binding mode of Staurosporine and origin of the selectivity of CGP 52411. J. Comput. Aided Mol. Des. 9: 465-472.
13. Gavin, A.C. and Nebreda, A.R. 1999. A MAP kinase docking site is required for phosphorylation and activation of p90(rsk)/MAPKAP kinase-1. Curr. Biol. 9: 281-284.
14. rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro. J. Biol. Chem. 272: 21281-21288.
15. Gray, N.S., Wodicka, L., Thunnissen, A.M., Norman, T.C., Kwon, S., Espinoza, F.H., Morgan, D.O., Barnes, G., LeClerc, S., Meijer, L., et al. 1998. Exploiting chemical libraries, structures, and genomics in the search of kinase inhibitors. Science 281: 533-538.
16. Huang, X., Begley, M., Morgenstern, K.A., Gu, Y., Rose, P., Zhao, H., and Zhu, X. 2003. Crystal structure of an inactive Akt2 kinase domain. Structure 11: 21-30.
17. Huse, M. and Kuriyan, J. 2002. The conformational plasticity of protein kinases. Cell 109: 275-282.
18. Jensen, C.J., Buch, M.B., Krag, T.O., Hemmings, B.A., Gammeltoft, S., and Frodin, M. 1999. 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositidedependent protein kinase-1. J. Biol. Chem. 274: 27168-27176.
19. Joel, P.B., Traish, A.M., and Lannigan, D.A. 1998. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J. Biol. Chem. 273: 13317-13323.
20. Jones, S.W., Erikson, E., Blenis, J., Maller, J.L., and Erikson, R.L. 1988. A Xenopus ribosomal S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc. Natl. Acad. Sci. 85: 3377-3381.
21. Kornienko, M., Montalvo, A., Carpenter, B.E., Lenard, M., Abeywickrema, P., Hall, D.L., Darke, P.L., and Kuo, L.C. 2005. Protein expression plasmids produced rapidly: Streamlining cloning protocols and robotic handling. Assay Drug Dev. Technol. 3: 661-674.
22. Lawrie, A.M., Noble, M.E., Tunnah, P., Brown, N.R., Johnson, L.N., and Endicott, J.A. 1997. Protein kinase inhibition by Staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 4: 796-801.
23. Leighton, I.A., Dalby, K.N., Caudwell, F.B., Cohen, P.T., and Cohen, P. 1995. Comparison of the specificities of p70 S6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 S6 kinase: The N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide phosphorylation. FEBS Lett. 375: 289-293.
24. McRee, D.E. 1999. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125: 156-165.
25. Meggio, F., Donella Deana, A., Ruzzene, M., Brunati, A.M., Cesaro, L., Guerra, B., Meyer, T., Mett, H., Fabbro, D., Furet, P., et al. 1995. Different susceptibility of protein kinases to Staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem. 234: 317-322.
26. Nowakowski, J., Cronin, C.N., McRee, D.E., Knuth, M.W., Nelson, C.G., Pavletich, N.P., Rogers, J., Sang, B., Scheibe, D.N., Swanson, R.V., et al. 2002. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 10: 1659-1667.
27. Otwinowski, Z. and Minor, W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307-326.
28. Palmer, P., Gavin, A.C., and Nebreda, A.R. 1998. A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) Phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1. EMBO J. 17: 5037-5047.
29. Poteet-Smith, C.E., Smith, J.A., Lannigan, D.A., Freed, T.A., and Sturgill, T.W. 1999. Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family. J. Biol. Chem. 274: 22135-22138.
30. Prade, L., Engh, R.A., Girod, A., Kinzel, V., Huber, R., and Bossemeyer, D. 1997. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 5: 1627-1637.
31. Richards, S.A., Fu, J., Romanelli, A., Shimamura, A., and Blenis, J. 1999. Ribosomal S6 kinase 1 (RSK1) activation requires signals dependent on and independent of the MAP kinase ERK. Curr. Biol. 9: 810-820.
32. Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P., and Blenis, J. 2004. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. 101: 13489-13494.
33. Sapkota, G.P., Cummings, L., Newell, F.S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., Hoffmann, M., Schnapp, G., Steegmaier, M., et al. 2007. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem. J. 401: 29-38.
34. Schouten, G.J., Vertegaal, A.C., Whiteside, S.T., Israel, A., Toebes, M., Dorsman, J.C., van der Eb, A.J., and Zantema, A. 1997. IκBα is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J. 16: 3133-3144.
35. Schubert, C., Schalk-Hihi, C., Struble, G., Ma, H., Petrounia, I., Brandt, B., Deckman, I.C., Patch, R.J., Player, M.R., Spurlino, J.C., et al. 2007. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 recpetor (cFMS) in complex with two inhibitors. J. Biol. Chem. 282: 4094-4101.
36. Schwab, M.S., Roberts, B.T., Gross, S.D., Tunquist, B.J., Taieb, F.E., Lewellyn, A.L., and Maller, J.L. 2001. Bub1 is activated by the protein kinase p90(Rsk) during Xenopus oocyte maturation. Curr. Biol. 11: 141-150.
37. Shaeffer, H.J. and Webber, M.J. 1999. Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol. Cell. Biol. 19: 2435-2444.
38. Smith, J.A., Poteet-Smith, C.E., Malarkey, K., and Sturgill, T.W. 1999. Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J. Biol. Chem. 274: 2893-2898.
39. Smith, K.J., Carter, P.S., Bridges, A., Horrocks, P., Lewis, C., Pettman, G., Clarke, A., Brown, M., Hughes, J., Wilkinson, M., et al. 2004. The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein. Structure 12: 1067-1077.
40. Smith, J.A., Poteet-Smith, C.E., Xu, Y., Errington, T.M., Hecht, S.M., and Lannigan, D.A. 2005. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 65: 1027-1034.
41. Sutherland, C., Leighton, I.A., and Cohen, P. 1993. Inactivation of glycogen synthase kinase-3h by phosphorylation: New kinase connections in insulin and growth-factor signalling. Biochem. J. 296: 15-19.
42. ++ dependent kinase. Biochem. Biophys. Res. Commun. 135: 397-402.
43. Xing, J., Ginty, D.D., and Greenberg, M.E. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273: 959-963.
44. Yang, J., Cron, P., Good, V.M., Thompson, V., Hemmings, B.A., and Barford, D. 2002. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 9: 940-944.
45. Zhao, B., Bower, M.J., McDevitt, P.J., Zhao, H., Davis, S.T., Johanson, K.O., Green, S.M., Concha, N.O., and Zhou, B.B. 2002. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 277: 46609-46615.
46. Zheng, J., Knighton, D.R., Ten Eyck, L.F., Karlsson, R., Xuong, N., Taylor, S.S., and Sowadski, J.M. 1993. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 32: 2154-2161.